You're not always 100% truthful (by omission) in your posts. You always overlook the of the value of the HDC platform drug products. All 400 plus drug linked products have potential to be useful in one type of cancer or another. The HDC Platform will more than likely bring huge value to SNTA stock from the potential of numerous partnerships, sole proprietary products and perhaps a merger or even acquisition. The science behind the HCD platform will bring about a business model similar to Seattle Genetics (SGEN) that will make this company soar.